Literature DB >> 13677583

Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care.

Larry Burd1, Marilyn G Klug, Matthew J Coumbe, Jacob Kerbeshian.   

Abstract

The objective of this study was to use population-based data to estimate the prevalence and cost of treatment for attention-deficit hyperactivity disorder (ADHD). The North Dakota Department of Health Claims Database was used to estimate the administrative prevalence, annual cost of care per case, and total annual cost of care for subjects with ADHD compared with controls. The case population was 7745, and the mean prevalence rate was 3.9%, with a peak prevalence at 10 years of age. For children with ADHD, the annual cost of care was 649 dollars compared with that of controls at 495 dollars. Cost of care attributable to ADHD was 649 dollars - 495 dollars = 54 dollars (31%). Utilization by children with ADHD with publicly funded payers was increased 25 to 175% over that of children with privately funded coverage. In North Dakota, the annual cost of care for children with ADHD was 5.1 million dollars, 5.6% of all health care costs for children. The annual attributable cost of care was 1.79 million dollars. Thus, 1.9% of total health expenditures for children was attributable to ADHD. In the United States, the cost of care attributable to children with ADHD would be 2.15 billion dollars annually.

Entities:  

Mesh:

Year:  2003        PMID: 13677583     DOI: 10.1177/08830738030180080101

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  23 in total

1.  Foreword -- ADHD in the scientific and political context.

Authors:  Jan K Buitelaar; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review.

Authors:  Anindit Chhibber; Alexandre Hikiji Watanabe; Chayutthaphong Chaisai; Sajesh K Veettil; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2021-02-08       Impact factor: 4.981

4.  Behavioral vaccines and evidence-based kernels: nonpharmaceutical approaches for the prevention of mental, emotional, and behavioral disorders.

Authors:  Dennis D Embry
Journal:  Psychiatr Clin North Am       Date:  2011-03

5.  Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

6.  Mothers of children diagnosed with attention-deficit/hyperactivity disorder: health conditions and medical care utilization in periods before and after birth of the child.

Authors:  G Thomas Ray; Lisa A Croen; Laurel A Habel
Journal:  Med Care       Date:  2009-01       Impact factor: 2.983

7.  Treatment costs of attention deficit hyperactivity disorder in Germany.

Authors:  Sebastian Braun; Jan Zeidler; Roland Linder; Susanne Engel; Frank Verheyen; Wolfgang Greiner
Journal:  Eur J Health Econ       Date:  2012-11-21

8.  Methylphenidate Effects on Cortical Thickness in Children and Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

Authors:  K B Walhovd; I Amlien; A Schrantee; D A Rohani; I Groote; A Bjørnerud; A M Fjell; L Reneman
Journal:  AJNR Am J Neuroradiol       Date:  2020-05       Impact factor: 3.825

Review 9.  Functional MRI in ADHD: a systematic literature review.

Authors:  Yannis Paloyelis; Mitul A Mehta; Jonna Kuntsi; Philip Asherson
Journal:  Expert Rev Neurother       Date:  2007-10       Impact factor: 4.618

10.  Association study of promoter polymorphisms at the dopamine transporter gene in Attention Deficit Hyperactivity Disorder.

Authors:  Xiaohui Xu; Jonathan Mill; Bo Sun; Chih-Ken Chen; Yu-Shu Huang; Yu-Yu Wu; Philip Asherson
Journal:  BMC Psychiatry       Date:  2009-02-05       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.